Bank of New York Mellon Corp lifted its holdings in shares of OptiNose Inc (NASDAQ:OPTN) by 1,054.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 178,289 shares of the company’s stock after purchasing an additional 162,851 shares during the quarter. Bank of New York Mellon Corp owned about 0.47% of OptiNose worth $4,987,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Wells Fargo & Company MN increased its stake in OptiNose by 60.0% in the second quarter. Wells Fargo & Company MN now owns 454,160 shares of the company’s stock valued at $12,708,000 after purchasing an additional 170,382 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of OptiNose during the second quarter worth approximately $417,000. State of Wisconsin Investment Board purchased a new position in shares of OptiNose during the second quarter worth approximately $464,000. Foresite Capital Management IV LLC grew its position in shares of OptiNose by 7.5% during the first quarter. Foresite Capital Management IV LLC now owns 483,606 shares of the company’s stock worth $9,682,000 after acquiring an additional 33,606 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of OptiNose by 5.7% during the first quarter. Northern Trust Corp now owns 79,072 shares of the company’s stock worth $1,583,000 after acquiring an additional 4,246 shares during the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.
OptiNose stock opened at $10.43 on Thursday. The firm has a market capitalization of $512.37 million and a price-to-earnings ratio of -1.92. The company has a debt-to-equity ratio of 0.44, a current ratio of 11.03 and a quick ratio of 10.82. OptiNose Inc has a one year low of $10.33 and a one year high of $30.00.
OptiNose (NASDAQ:OPTN) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.13. The firm had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.01 million. On average, analysts predict that OptiNose Inc will post -2.94 earnings per share for the current year.
A number of brokerages have recently issued reports on OPTN. Cantor Fitzgerald set a $30.00 target price on shares of OptiNose and gave the stock a “buy” rating in a research report on Tuesday, August 14th. Zacks Investment Research raised OptiNose from a “sell” rating to a “hold” rating in a report on Friday, June 15th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $34.00 price target on shares of OptiNose in a report on Wednesday, July 18th. Finally, BMO Capital Markets decreased their price target on OptiNose from $30.00 to $28.00 and set an “outperform” rating for the company in a report on Wednesday, August 15th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. OptiNose currently has an average rating of “Buy” and a consensus price target of $29.67.
In related news, insider Thomas Edward Gibbs acquired 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The stock was purchased at an average price of $12.69 per share, for a total transaction of $25,380.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Peter K. Miller acquired 10,752 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were bought at an average price of $14.32 per share, with a total value of $153,968.64. The disclosure for this purchase can be found here. Insiders own 67.80% of the company’s stock.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
See Also: Stock Symbol
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.